CO2020010226A2 - Terapia con oligonucleotidos para la enfermedad de wilson - Google Patents
Terapia con oligonucleotidos para la enfermedad de wilsonInfo
- Publication number
- CO2020010226A2 CO2020010226A2 CONC2020/0010226A CO2020010226A CO2020010226A2 CO 2020010226 A2 CO2020010226 A2 CO 2020010226A2 CO 2020010226 A CO2020010226 A CO 2020010226A CO 2020010226 A2 CO2020010226 A2 CO 2020010226A2
- Authority
- CO
- Colombia
- Prior art keywords
- exon
- atp7b
- wilson
- disease
- flanking
- Prior art date
Links
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 title abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- 208000018839 Wilson disease Diseases 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 102100027591 Copper-transporting ATPase 2 Human genes 0.000 abstract 4
- 101000936280 Homo sapiens Copper-transporting ATPase 2 Proteins 0.000 abstract 4
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 2
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 2
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
- C12Y306/03004—Cu2+-exporting ATPase (3.6.3.4)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630565P | 2018-02-14 | 2018-02-14 | |
| PCT/US2019/018076 WO2019161105A1 (en) | 2018-02-14 | 2019-02-14 | Oligonucleotide therapy for wilson disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020010226A2 true CO2020010226A2 (es) | 2020-12-10 |
Family
ID=67619598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0010226A CO2020010226A2 (es) | 2018-02-14 | 2020-08-19 | Terapia con oligonucleotidos para la enfermedad de wilson |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11578327B2 (enExample) |
| EP (1) | EP3752614A4 (enExample) |
| JP (1) | JP2021513851A (enExample) |
| KR (1) | KR20200120675A (enExample) |
| CN (1) | CN112041439A (enExample) |
| AU (1) | AU2019222767A1 (enExample) |
| BR (1) | BR112020016524A2 (enExample) |
| CA (1) | CA3090517A1 (enExample) |
| CL (1) | CL2020002100A1 (enExample) |
| CO (1) | CO2020010226A2 (enExample) |
| IL (1) | IL276701A (enExample) |
| MX (1) | MX2020008533A (enExample) |
| PH (1) | PH12020551219A1 (enExample) |
| SG (1) | SG11202007644PA (enExample) |
| WO (1) | WO2019161105A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025110984A1 (en) * | 2023-11-21 | 2025-05-30 | Hydrogene Therapeutics, Inc. | Compositions and methods for treating wilson's disease |
| CN117925624B (zh) * | 2024-03-22 | 2024-05-31 | 上海凌医生物科技有限公司 | 一种金属响应调控元件 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US5578493A (en) * | 1993-09-01 | 1996-11-26 | The Trustees Of Columbia University In The City Of New York | Wilson's disease gene |
| CA2108927C (en) | 1993-09-21 | 2008-09-02 | Peter Bull | Wilson disease gene |
| CN1120707C (zh) | 1995-11-22 | 2003-09-10 | 约翰斯·霍普金斯大学 | 增强生物分子的细胞摄取的配体 |
| US20040101854A1 (en) * | 2002-11-21 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of BCL2-associated athanogene expression |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US20030180953A1 (en) | 2000-12-29 | 2003-09-25 | Elitra Pharmaceuticals, Inc. | Gene disruption methodologies for drug target discovery |
| US20040126761A1 (en) * | 2002-12-10 | 2004-07-01 | Isis Pharmaceuticals Inc. | Modulation of alpha-methylacyl-CoA racemase expression |
| EP1556510A2 (en) | 2002-10-21 | 2005-07-27 | Exiqon A/S | Oligonucleotide analogues for detecting and analyzing nucleic acids |
| US20050244851A1 (en) | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
| CN1925869A (zh) * | 2004-01-29 | 2007-03-07 | 塞尔卓姆股份公司 | 使用gpr49治疗神经变性疾病 |
| WO2005116204A1 (ja) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| JP5697297B2 (ja) | 2004-05-14 | 2015-04-08 | ロゼッタ ジノミクス リミテッド | マイクロｎａｓおよびその使用 |
| US20070048756A1 (en) | 2005-04-18 | 2007-03-01 | Affymetrix, Inc. | Methods for whole genome association studies |
| EP1783645A1 (en) * | 2005-11-08 | 2007-05-09 | Actigenics | Methods for the identification of microRNA and their applications in research and human health |
| US8178503B2 (en) | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
| JP4841279B2 (ja) | 2006-03-23 | 2011-12-21 | 一般財団法人 化学物質評価研究機構 | 被検物質の発がん性予測方法 |
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| EP2802658A2 (en) * | 2012-01-09 | 2014-11-19 | Novartis AG | Rnai agents to treat beta-catenin related diseases |
| WO2014036301A1 (en) * | 2012-08-30 | 2014-03-06 | Isis Pharmaceuticals, Inc. | Modulation of copper related diseases by ctr1 |
| DK2992098T3 (da) | 2013-05-01 | 2019-06-17 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression |
| US20160258005A1 (en) * | 2013-07-02 | 2016-09-08 | The Trustees Of The University Of Pennsylvania | Methods for rapid ribonucleic acid fluorescence in situ hybridization |
| EP3066105A4 (en) | 2013-11-06 | 2017-10-11 | Solstice Biologics, Ltd. | Polynucleotide constructs having disulfide groups |
| CA2950960A1 (en) | 2014-06-06 | 2015-12-10 | Solstice Biologics, Ltd. | Polynucleotide constructs having bioreversible and non-bioreversible groups |
| WO2016004043A1 (en) | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| CA2964979A1 (en) | 2014-11-14 | 2016-05-19 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of proteins |
| HK1246690A1 (zh) | 2015-01-21 | 2018-09-14 | Sangamo Therapeutics, Inc. | 用於鉴定高度特异性核酸酶的方法和组合物 |
| CN105986015B (zh) * | 2015-02-05 | 2020-10-23 | 大连晶泰生物技术有限公司 | 一种基于高通量测序的多样本的一个或多个靶序列的检测方法和试剂盒 |
| US20180305689A1 (en) | 2015-04-22 | 2018-10-25 | Mina Therapeutics Limited | Sarna compositions and methods of use |
| WO2017100461A1 (en) | 2015-12-08 | 2017-06-15 | Solstice Biologics, Ltd. | Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate |
| JP2019500345A (ja) * | 2015-12-14 | 2019-01-10 | コールド スプリング ハーバー ラボラトリー | 肝臓病の処置のための組成物および方法 |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| KR101743211B1 (ko) | 2016-06-24 | 2017-06-15 | 주식회사 녹십자지놈 | 선천성 기능장애 진단용 조성물 및 이의 용도 |
| EP3840758A1 (en) * | 2018-08-21 | 2021-06-30 | Deep Genomics Incorporated | Therapeutic splice-switching oligonucleotides |
| AU2022271873A1 (en) * | 2021-05-10 | 2024-01-04 | Entrada Therapeutics, Inc. | Compositions and methods for intracellular therapeutics |
| WO2022256283A2 (en) * | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
-
2019
- 2019-02-14 PH PH1/2020/551219A patent/PH12020551219A1/en unknown
- 2019-02-14 EP EP19754072.7A patent/EP3752614A4/en active Pending
- 2019-02-14 CA CA3090517A patent/CA3090517A1/en active Pending
- 2019-02-14 CN CN201980018495.1A patent/CN112041439A/zh active Pending
- 2019-02-14 BR BR112020016524-7A patent/BR112020016524A2/pt not_active IP Right Cessation
- 2019-02-14 MX MX2020008533A patent/MX2020008533A/es unknown
- 2019-02-14 JP JP2020543576A patent/JP2021513851A/ja not_active Withdrawn
- 2019-02-14 KR KR1020207025862A patent/KR20200120675A/ko not_active Withdrawn
- 2019-02-14 WO PCT/US2019/018076 patent/WO2019161105A1/en not_active Ceased
- 2019-02-14 AU AU2019222767A patent/AU2019222767A1/en not_active Abandoned
- 2019-02-14 SG SG11202007644PA patent/SG11202007644PA/en unknown
- 2019-02-14 US US16/970,088 patent/US11578327B2/en active Active
-
2020
- 2020-08-13 IL IL276701A patent/IL276701A/en unknown
- 2020-08-13 CL CL2020002100A patent/CL2020002100A1/es unknown
- 2020-08-19 CO CONC2020/0010226A patent/CO2020010226A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020002100A1 (es) | 2021-01-29 |
| JP2021513851A (ja) | 2021-06-03 |
| EP3752614A4 (en) | 2021-11-10 |
| CN112041439A (zh) | 2020-12-04 |
| BR112020016524A2 (pt) | 2021-09-28 |
| WO2019161105A1 (en) | 2019-08-22 |
| KR20200120675A (ko) | 2020-10-21 |
| IL276701A (en) | 2020-09-30 |
| SG11202007644PA (en) | 2020-09-29 |
| PH12020551219A1 (en) | 2021-04-19 |
| US20210032629A1 (en) | 2021-02-04 |
| MX2020008533A (es) | 2020-11-06 |
| AU2019222767A1 (en) | 2020-08-27 |
| CA3090517A1 (en) | 2019-08-22 |
| EP3752614A1 (en) | 2020-12-23 |
| US11578327B2 (en) | 2023-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001490A1 (es) | Constructos de iarn modificados químicamente y usos de estos | |
| MX2023006467A (es) | Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos. | |
| NZ733882A (en) | Compositions for modulating c9orf72 expression | |
| CO2019003846A2 (es) | Tratamiento aav de la enfermedad de huntington | |
| MX2025007610A (es) | Composiciones de arni de 17beta-hidroxiesteroide deshidrogenasa tipo 13 (hsd17b13) y metodos de uso de las mismas | |
| MX2024000329A (es) | Compuestos bifuncionales que comprenden una molecula que contiene una porcion dirigida a la proteina smarca (ptm) enlazada a una porcion de una molecula de union de ligasa de ubiquitina e3 (ulm), y su uso como moduladores de la ubiquitinacion dirigidos al tratamiento del cancer. | |
| EP4494706A3 (en) | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases | |
| CO2021009163A2 (es) | Composiciones de agente de arni de proteína precursora de amiloide (app) y método de uso de las mismas | |
| AR107579A1 (es) | Composiciones y métodos para disminuir la expresión de tau | |
| NZ747685A (en) | Oligonucleotide analogues targeting human lmna | |
| CL2024001319A1 (es) | Composiciones de arni del factor b del complemento (cfb) y métodos de uso | |
| CR20190294A (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO | |
| MX2017002144A (es) | Agentes de ácido ribonucleico (arn) de cadena doble modificados. | |
| UY40039A (es) | COMPOSICIONES DE ARNi DEL COMPONENTE DEL COMPLEMENTO C5 Y MÉTODOS PARA SU USO | |
| MX2022004388A (es) | Composiciones de agentes de arni de huntingtina (htt) y metodos de uso de las mismas. | |
| CL2021001488A1 (es) | Transposasa de piggybac mutada | |
| CY1123639T1 (el) | Μονοκλωνα ολιγονουκλεοτιδια για χρηση στην ιατρικη θεραπευτικη αντιμετωπιση διαταραχων του δερματος | |
| NZ741841A (en) | Antisense oligonucleotides for use in treating alzheimer’s disease | |
| CO2020010226A2 (es) | Terapia con oligonucleotidos para la enfermedad de wilson | |
| MX388737B (es) | Oligonucleótidos terapéuticos. | |
| CO2026004373A2 (es) | Composiciones de oligonucleótidos de cadena doble relacionadas con la subunidad beta e de la inhibina y métodos relacionados con estas | |
| CY1123599T1 (el) | Συνθεσεις και μεθοδοι για τη διορθωση ζωνιαιας μυικης δυστροφιας τυπου 2c με τη χρησιμοποιηση παραλειψης εξονιων | |
| MX2025000726A (es) | Composiciones de oligonucleótidos y métodos para éstas | |
| MX2023015395A (es) | Tratamiento de enfermedades y trastornos relacionados con mst1. | |
| AR112270A1 (es) | Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia |